Back to Search
Start Over
In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors
- Source :
- BMC Cancer
- Publisher :
- Springer Nature
-
Abstract
- Background Cancer stem cells (CSCs) are considered the cell subpopulation responsible for breast cancer (BC) initiation, growth, and relapse. CSCs are identified as self-renewing and tumor-initiating cells, conferring resistance to chemo- and radio-therapy to several neoplasias. Nowadays, th (about 10mM)e pharmacological targeting of CSCs is considered an ineludible therapeutic goal. The antidiabetic drug metformin was reported to suppress in vitro and in vivo CSC survival in different tumors and, in particular, in BC preclinical models. However, few studies are available on primary CSC cultures derived from human postsurgical BC samples, likely because of the limited amount of tissue available after surgery. In this context, comparative oncology is acquiring a relevant role in cancer research, allowing the analysis of larger samples from spontaneous pet tumors that represent optimal models for human cancer. Methods Isolation of primary canine mammary carcinoma (CMC) cells and enrichment in stem-like cell was carried out from fresh tumor specimens by culturing cells in stem-permissive conditions. Phenotypic and functional characterization of CMC-derived stem cells was performed in vitro, by assessment of self-renewal, long-lasting proliferation, marker expression, and drug sensitivity, and in vivo, by tumorigenicity experiments. Corresponding cultures of differentiated CMC cells were used as internal reference. Metformin efficacy on CMC stem cell viability was analyzed both in vitro and in vivo. Results We identified a subpopulation of CMC cells showing human breast CSC features, including expression of specific markers (i.e. CD44, CXCR4), growth as mammospheres, and tumor-initiation in mice. These cells show resistance to doxorubicin but were highly sensitive to metformin in vitro. Finally, in vivo metformin administration significantly impaired CMC growth in NOD-SCID mice, associated with a significant depletion of CSCs. Conclusions Similarly to the human counterpart, CMCs contain stem-like subpopulations representing, in a comparative oncology context, a valuable translational model for human BC, and, in particular, to predict the efficacy of antitumor drugs. Moreover, metformin represents a potential CSC-selective drug for BC, as effective (neo-)adjuvant therapy to eradicate CSC in mammary carcinomas of humans and animals. Electronic supplementary material The online version of this article (doi:10.1186/s12885-015-1235-8) contains supplementary material, which is available to authorized users.
- Subjects :
- Pathology
medicine.medical_specialty
Cancer Research
Cell Survival
Antineoplastic Agents
Breast Neoplasms
Mammary Neoplasms, Animal
CXCR4
Mice
Breast cancer
Dogs
Cancer stem cell
In vivo
Surgical oncology
Cell Line, Tumor
Genetics
Animals
Humans
Medicine
Cell Proliferation
Canine Mammary Carcinoma
Comparative oncology
biology
Cancer stem cells
business.industry
CD44
Estrogen Receptor alpha
Xenograft Model Antitumor Assays
Metformin
ErbB Receptors
Disease Models, Animal
Hyaluronan Receptors
Ki-67 Antigen
Phenotype
Oncology
Drug Resistance, Neoplasm
Cell culture
Neoplastic Stem Cells
biology.protein
Cancer research
Female
Stem cell
business
Research Article
Subjects
Details
- Language :
- English
- ISSN :
- 14712407
- Volume :
- 15
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- BMC Cancer
- Accession number :
- edsair.doi.dedup.....3299e6497783f5e84ae8972409a31125
- Full Text :
- https://doi.org/10.1186/s12885-015-1235-8